Expand ASND Menu
ASND MENU

ASND Latest Press Releases

-- February 11, 2026 --

Ascendis Pharma Reports Fourth Quarter and Full-Year 2025 Financial Results Globe Newswire 4:01 PM

-- February 4, 2026 --

Ascendis Pharma to Report Full Year 2025 Financial Results and Provide Business Update on February 11, 2026 Globe Newswire 4:01 PM

-- January 9, 2026 --

Ascendis Pharma Provides Business and Strategic Roadmap Update at 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 6:01 PM

-- January 8, 2026 --

Week 52 COACH Trial Topline Results Confirm Consistent and Durable Treatment Benefits in Children with Achondroplasia (ACH) Globe Newswire 4:01 PM

-- January 5, 2026 --

Ascendis Pharma to Participate in the 44th Annual J.P. Morgan Healthcare Conference Globe Newswire 8:30 AM

-- November 25, 2025 --

Ascendis Announces Extension of FDA Review Period for TransCon CNP (navepegritide) for Children with Achondroplasia Globe Newswire 6:15 PM

-- November 17, 2025 --

Results of Pivotal ApproaCH Trial of TransCon CNP (Navepegritide) in Children with Achondroplasia Published in JAMA Pediatrics Globe Newswire 4:01 PM

-- November 12, 2025 --

Ascendis Pharma Reports Third Quarter 2025 Financial Results Globe Newswire 4:01 PM

-- November 7, 2025 --

New Pooled 3-Year Analysis Confirms Sustained, Clinically Meaningful Improvements in Renal Function for TransCon PTH (Palopegteriparatide)-Treated Adults with Hypoparathyroidism Globe Newswire 8:30 AM

-- November 5, 2025 --

Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 Globe Newswire 4:01 PM

-- November 3, 2025 --

3-Year Renal Data in Adults with Hypoparathyroidism Treated with TransCon PTH (Palopegteriparatide) to Be Shared at Kidney Week 2025 Globe Newswire 4:01 PM

-- October 8, 2025 --

Ascendis Submits Marketing Authorisation Application to the European Medicines Agency for TransCon CNP for Treatment of Children with Achondroplasia Globe Newswire 4:01 PM
Market Data Delayed 15 Minutes